Last reviewed · How we verify
NCT06825793
Semaglutide's Weight Loss Effects in Obesity
NA trial testing Semaglutide Subcutaneous Injection in Obesity in 56 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Beijing Chao Yang Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 56 |
| Start date | 20 February 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Semaglutide Subcutaneous Injection — full drug profile →
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Beijing Chao Yang Hospital
Who can join
Adults 18 to 60, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06825793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Semaglutide Subcutaneous Injection
Trials testing the same drug.
- NCT07281196 — Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea · completed
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Beijing Chao Yang Hospital trials
Trials by the same sponsor.
- NCT07520305 — Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes · NA · not yet recruiting
- NCT07490925 — Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS · NA · not yet recruiting
- NCT07382986 — IMPACT COPD Cohort (China) · recruiting
- NCT07323134 — The Effect of Semaglutide on the Intestinal Flora in Obesity · not yet recruiting
- NCT07049692 — Hyperbaric Oxygen After Stroke Thrombectomy: A Multicenter Randomized Trial on Safety and Efficacy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06825793 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Chao Yang Hospital
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06825793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing